tert-butyl (4-amino-2-trifluoromethylbenzyl)carbamate | 942077-17-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (4-amino-2-trifluoromethylbenzyl)carbamate
• 英文别名: Tert-butyl [4-amino-2-(trifluoromethyl)benzyl]carbamate；tert-butyl N-[[4-amino-2-(trifluoromethyl)phenyl]methyl]carbamate
• CAS: 942077-17-0
• 化学式: C₁₃H₁₇F₃N₂O₂
• 分子量: 290.285
• InChiKey: FIEVJXFYSNFUGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl (4-amino-2-trifluoromethylbenzyl)carbamate 、 甲基磺酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl 4-(methylsulfonamido)-2-(trifluoromethyl)-benzylcarbamate
  参考文献：
  名称：

  Synthesis and structural optimization of multiple H-bonding region of diarylalkyl (thio)amides as novel TRPV1 antagonists

  摘要：

  Structural optimization of multiple H-bonding region and structure-activity relationship of diarylalkyl amides/thioamides as novel TRPV1 antagonists are described. In particular, we identified amide 34o and thioamides 35o and 35r, of which antagonistic activities were highly enhanced by an incorporation of cyano or vinyl-substituent to the multiple H-bonding region. They exhibited potent Ca-45(2+) uptake inhibitions in rat DRG neuron with IC(50)s of 25, 32 and 28 nM, respectively. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.10.043
• 作为产物：
  描述：

  4-(aminomethyl)-3-(trifluoromethyl)aniline 、 二碳酸二叔丁酯 在 silica 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以to give tert-butyl [4-amino-2-(trifluoromethyl)benzyl]carbamate as yellow solid的产率得到tert-butyl (4-amino-2-trifluoromethylbenzyl)carbamate
  参考文献：
  名称：

  Bicyclic compounds with kinase inhibitory activity

  摘要：

  本发明提供了一种新颖的双环化合物，可用作蛋白激酶抑制剂。本发明还提供了包括本发明化合物的制药组合物以及使用该组合物治疗各种疾病的方法。

  公开号：

  US20070149533A1

文献信息

• BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS
  申请人：AVERSA Robert

  公开号：US20160038504A1

  公开（公告）日：2016-02-11

  The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

  本发明提供了式（I）所述的化合物及其盐，并且提供了这些化合物用于治疗与Raf激酶活性相关的疾病的治疗用途。本发明还提供了包含这些化合物的制药组合物，以及包含这些化合物和治疗联合剂的组合物。
• Biaryl amide compounds as kinase inhibitors
  申请人：NOVARTIS AG

  公开号：US10245267B2

  公开（公告）日：2019-04-02

  The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

  本发明提供了本文所述的式(I)化合物及其盐类，以及这些化合物治疗与Raf激酶活性相关疾病的治疗用途。本发明进一步提供了包含这些化合物的药物组合物，以及包含这些化合物和一种治疗辅助试剂的组合物。
• US8802850B2
  申请人：——

  公开号：US8802850B2

  公开（公告）日：2014-08-12
• US9694016B2
  申请人：——

  公开号：US9694016B2

  公开（公告）日：2017-07-04
• [EN] BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS BIARYLE AMIDES EN TANT QU'INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2014151616A1

  公开（公告）日：2014-09-25

  The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.